Abstract:Alzheimer's disease (AD) is a neurodegenerative illness associated with amyloid β-peptide (Aβ) aggregation in the brain. Aβ shows high affinity for metal ions such as Zn2+ and Cu2+, which constitutes the major reason for the Aβ aggregation and related neurotoxicity. Metal chelators are potential therapeutic agents for AD because they could sequester metal ions from the Aβ aggregates and reverse the aggregation. In this study, two macrocyclic platiniferous chelators (PC1, PC2) with cyclen as the metal-chelating unit and Pt(bipyridine)Cl2 as the Aβ-binding unit have been designed as novel bifunctional inhibitors of the metal-induced Aβ aggregation. The interactions between the chelators and Aβ40 aggregates are studied by tandem mass spectrometry and 1H NMR. The platinum centers in PC1 and PC2 are shown to coordinate with histidine residues (His-14 or -13) of Aβ40. The inhibitory effect of the chelators on Aβ40 aggregation induced by Zn2+ and Cu2+ ions is investigated using turbidimetry, a BCA protein assay, and transmission electron microscopy. PC1 and PC2 show significant inhibition against the Aβ aggregation and the action is more effective than that exerted by cyclen. By contrast, the corresponding anticancer drug cisplatin exhibits no inhibition against the Aβ aggregation. PC1 and PC2 can also suppress the Cu-Aβ40 mediated generation of reactive oxygen species and their corresponding neurotoxicity in cortical neuronal cells of mice, and reduce the extent of Aβ aggregation in the brain homogenates of transgenic mice. These chelators may work through simultaneous metal chelation and peptide modification to interfere with the Aβ aggregation. Such an intramolecular synergism distinguishes PC1 and PC2 from other chelators as potential anti-AD agents.

Structure and mechanism behind the inhibitory effect of water soluble metalloporphyrins on Aβ 1–42 aggregation

Metal-Ion Modulated Structural Transformation of Amyloid-Like Dipeptide Supramolecular Self-Assembly

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

Synthesis and Biological Evaluation of Deferiprone-Resveratrol Hybrids As Antioxidants, Aβ1–42 Aggregation Inhibitors and Metal-Chelating Agents for Alzheimer's Disease

Metal-Organic Frameworks Harness Cu Chelating and Photooxidation Against Amyloid β Aggregation in Vivo

A Relationship between the Structures and Neurotoxic Effects of Aβ Oligomers Stabilized by Different Metal Ions

Inhibitory Action of Macrocyclic Platiniferous Chelators on Metal-Induced Aβ Aggregation

Porous organic cage as an inhibitor of Aβ42 peptide: a simulation study

Dual Functions of Beta-Amyloid Oligomer and Fibril in Cu(Ii)-Induced H2o2 Production

Effect of metal chelators on the aggregation of beta-amyloid peptides in the presence of copper and iron

Copolymer Polydopamine Nanoparticles as Multifunctional Nanoinhibitors for Modulating β-Amyloid Aggregation

Synergistic Inhibitory Effect of Peptide-Organic Coassemblies on Amyloid Aggregation.

Mechanistic approaches for chemically modifying the coordination sphere of copper–amyloid-β complexes

Impact of Au144 metal clusters on the structural and inhibitory mechanism of Aβ42 peptide: A theoretical approach

Understanding the Molecular Mechanisms of Polyphenol Inhibition of Amyloid β Aggregation

Comparative Analysis of the Inhibitory Mechanism of Aβ 1-42 Aggregation by Diruthenium Complexes

The mechanism for heme to prevent Aβ 1–40 aggregation and its cytotoxicity

Inhibition of metal-induced amyloid aggregation using light-responsive magnetic nanoparticle prochelator conjugates

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Metal ion coordination delays amyloid-β peptide self-assembly by forming an aggregation–inert complex

Modulation of Amyloid-β Conformation by Charge State of N-Terminal Disordered Region